Literature DB >> 6224125

[Comparative in vitro effect of 7 quinolones on Ureaplasma urealyticum].

P Cantet, H Renaudin, C Quentin, C Bebear.   

Abstract

Some new quinolones may be used for the treatment of gonococcal urethritis. U. urealyticum is considered as a potential agent of urethritis. This report describes the in vitro antimicrobial activity of seven quinolones against 45 clinical isolates of U. urealyticum. The MIC's geometric mean is (microgram/ml): rosoxacin (1,74), pefloxacin (4,6), oxolinic acid (9), flumequin (12,12), norfloxacin (15,75), nalidixic acid (27). Pipemidic acid is constantly inactive (greater than 128 micrograms/ml). The results of these susceptibility studies provide support for undertaking clinical evaluations of new quinolones against infections with U. urealyticum.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224125

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  5 in total

1.  Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Authors:  G E Kenny; T M Hooton; M C Roberts; F D Cartwright; J Hoyt
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 2.  Alternative therapy for genital mycoplasma infections.

Authors:  J A Robertson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

3.  In vitro activity of amifloxacin against Chlamydia trachomatis and Ureaplasma urealyticum.

Authors:  S Freeman; J Wormuth; J Cornett
Journal:  Eur J Clin Microbiol       Date:  1985-10       Impact factor: 3.267

Review 4.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

5.  In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.

Authors:  K B Waites; L B Duffy; T Schmid; D Crabb; M S Pate; G H Cassell
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.